Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswireJanuary 3, 2020ReblogShareTweetShareBRIDGEWATER, N.J., Jan. 3, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commencement of their employment, the employees received options on January 2, 2020 to purchase an aggregate 192,660 shares of Insmed common stock at an exercise price of $23.66 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.The options have a ten-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.About InsmedInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.Contact:Blaine DavisHead of Investor Relations and Corporate CommunicationsInsmed Incorporated(732) 487-7310blaine.davis@insmed.com(PRNewsfoto/Insmed Incorporated)More CisionMoreView original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-300980999.htmlSOURCE Insmed IncorporatedReblogShareTweetShareRecently ViewedYour list is empty.What to Read Next5 Things You Should Know About Spinal Muscular AtrophyThe MightyValley tech companies see limited coronavirus impact; analyst warns it could be comingAmerican City Business JournalsIn a week of losers, these Oregon stocks fared the worstAmerican City Business JournalsThe Dow Jones drops nearly 1,200 points as coronavirus fears batter stock marketsTechCrunchDow Plunges 1,200 Points As Stock Market Melts Down Again On Coronavirus FearsInvestor's Business DailyRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoTimeless Software (HKG:8028) Shareholders Have Enjoyed A 51% Share Price GainSimply Wall St.Biocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video